Fig. 9From: Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review articleAUGUSTUS trial (2019): Primary outcomes of major/clinically relevant bleeding, showing significant high bleeding in the TAT group compared to DAT. *Note: all patients received P2Y12 inhibitor besides the given medications [25]. https://doi.org/10.1056/NEJMoa1817083Back to article page